How a Provider-Led Longevity Program Works, and What It Costs

Search for "NAD+ therapy" or "longevity program" online and you'll find a handful of telehealth companies offering to evaluate you, prescribe something, and ship it to your door. The pitch sounds simple. What's less obvious from the landing page is what's actually included in the number you're quoted, and why the same program can be available to your neighbor but not to you.

The price usually covers more than the medication

Traditional healthcare tends to itemize: a visit fee here, a lab fee there, a separate pharmacy bill for whatever gets prescribed. Some provider-led longevity programs work differently. They quote one flat price that's meant to include the online evaluation, the medication itself, and the provider visits that go with it, with no separate membership fee layered on top.

That structure is a choice a program makes, not a universal rule for the category. Before you compare two programs on price, check whether they're actually describing the same bundle. A monthly figure that excludes the intake evaluation, or bills follow-up visits separately, isn't cheaper than a flat price that includes both. It just moves the cost somewhere else in the copy.

What a flat price does not remove is the evaluation itself. A program built this way still requires an online intake and a review by licensed providers before anything ships. The price covers what happens after that review, not a guarantee that you'll be approved. Learn how the pricing, eligibility, and access rules for these programs actually work before you request a consult.

Why eligibility isn't the same in every state

Compounded medications, including the NAD+ and peptide-based options these programs prescribe, aren't manufactured and approved the way a standard pharmacy drug is. They're prepared by a compounding pharmacy from a bulk substance, under a separate regulatory framework. The FDA maintains a running list of which bulk substances it considers acceptable for this kind of compounding, and that list changes as new substances are reviewed. In other words, whether a given peptide can legally be compounded at all is a live regulatory question, not a fixed fact.

State law adds another layer on top of that federal question. A program can be operating legally in most of the country and still be unavailable, or restricted, in a handful of states. That's decided during the online evaluation, not before you sign up, which is why "am I eligible" can't be answered from the homepage alone.

What the compounding pharmacy is expected to do

Sterile compounding, the kind used for an injectable NAD+ or peptide product, is governed by a US Pharmacopeia standard that sets requirements for the personnel, training, facility conditions, and testing a compounding pharmacy has to follow. That standard exists because a compounded sterile product is being prepared as an individual batch, not manufactured on an assembly line with FDA product approval attached to it. The FDA states the same point plainly about this whole category: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before they reach a patient. Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.

None of that makes compounding unsafe by definition. It means the safety burden shifts from a product-approval process to a pharmacy's adherence to that preparation standard, plus the judgment of the licensed provider deciding whether to prescribe it to you at all. What a program tells you up front about its own structure is worth reading closely before you assume any two work the same way; the Luvo Health longevity program page describes a flat price with no membership fee that includes the medication and the provider visits, with eligibility for compounded therapies decided during the evaluation.

What a certification like LegitScript actually verifies

Programs in this space often advertise a LegitScript certification. It's worth knowing what that label does and doesn't mean. LegitScript describes its certification as a compliance review for companies in high-risk, regulated industries, and the practical effect is that a certified healthcare merchant becomes eligible to advertise on the major ad platforms and to accept digital payments. That is a real gate, and plenty of operators don't clear it.

It is not the same thing as FDA approval of the product being sold. A platform can be fully certified while every medication it dispenses is a compounded product that has never gone through the FDA approval process the way a brand-name prescription drug has. The certification tells you something about the business. It tells you nothing about the science behind any specific compound.

What the research actually supports

Some of the compounds used in these programs, like nicotinamide riboside, a precursor the body converts into NAD+, have real published research behind them. A randomized, placebo-controlled trial of 140 healthy, overweight adults aged 40 to 60 found that eight weeks of daily nicotinamide riboside raised blood NAD+ in a dose-dependent way, with no meaningful difference in adverse events compared to placebo. That's a legitimate finding about raising a specific biomarker in a specific population over a specific window of time. It's a study of an oral supplement, not the injectable, drop, or nasal-spray forms a telehealth program might prescribe, and it says nothing about longevity, disease prevention, or any other outcome that trial didn't measure.

That gap between what a study actually tested and what marketing copy implies is worth carrying into how you read any program's site. A flat price and a clean checkout flow don't change what the underlying evidence does or doesn't support, and no program can promise you a specific result. If a provider-led model at least matches your budget and your state's eligibility rules, the Luvo Health longevity program page is one place to see how the evaluation and pricing are laid out before you commit to anything.

Sources

• USP General Chapter <797>, Pharmaceutical Compounding, Sterile Preparations: https://www.usp.org/compounding/general-chapter-797. Not a clinical study; sets sterile compounding requirements for personnel, training, facilities, and testing; applies to anyone preparing compounded sterile preparations including injectables; a quality standard, not a pricing or eligibility framework.
• FDA, Bulk Drug Substances list and Category 2 safety-risk determinations for 503A/503B compounding: https://www.fda.gov/media/94164/download. Not a clinical study; an ongoing FDA determination of which bulk substances are acceptable for compounding; shows compounding eligibility for any given peptide changes over time and isn't fixed.
• U.S. Food and Drug Administration, "Compounding and FDA: Questions and Answers": https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. Not a clinical study; the agency's description of the compounding pathway, including sterile injectables prepared under section 503A; states that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before they reach a patient; a regulatory description, not evidence about any specific compound.
• LegitScript, Certification: https://www.legitscript.com/certification/. Not a clinical study; the certifier's own description of its healthcare merchant certification as a compliance review that lets certified businesses advertise on major platforms and accept digital payments; describes a commercial compliance gate, not product efficacy or FDA approval.
• Airhart et al., "Safety and Metabolism of Long-term Administration of NIAGEN," PLOS ONE, 2019: https://pmc.ncbi.nlm.nih.gov/articles/PMC6611812/. 140 healthy, overweight adults, ages 40 to 60; oral nicotinamide riboside chloride, 100 to 1000 mg daily; 8-week randomized, double-blind, placebo-controlled trial; dose-dependent NAD+ increase with no significant difference in adverse events versus placebo; studied an oral precursor, not the injectable or nasal forms these programs may prescribe, and not a cost or access study.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.